BioPharm Insight™ to Host Complimentary Webinar on Pain Drugs in Development Featuring Expert Physician Panel

Share Article

Dr. Edgar Ross and Dr. Lynn Webster to examine drug pipelines, FDA approval issues and risk mitigation plans.

On September 26 at 10am ET, BioPharm Insight will host “The Pain Pipeline,” a live online seminar discussing pain drugs in development with two expert physicians. This session is the latest entry in BioPharm Insight’s ongoing series of complimentary and educational webinars. Register to attend the webinar.

Featuring presentations by subject matter experts Dr. Edgar Ross of the Pain Management Center at Brigham and Women’s Hospital and Dr. Lynn Webster of the Lifetree Clinical Research and Pain Clinic, the session will cover critical drug development topics including:

  •     Pain drug pipeline and study sponsor updates
  •     FDA approval challenges
  •     Risk mitigation strategies and more

Moderated by Jennifer Smith-Parker, Assistant Editor at BioPharm Insight, the webinar will last approximately 60 minutes and feature an interactive Q&A session with attendees.

If you can’t attend the live session, request a recording after the event.

About BioPharm Insight
BioPharm Insight is the definitive guide to the global life sciences community, combining forward-looking intelligence uncovered by an independent team of investigative journalists with the most comprehensive and powerful real-time database of market analytics and key contact information. BioPharm Insight is used by biopharma companies, CROs, service providers and financial markets firms to understand and interact with their industry. For a free trial of BioPharm Insight, visit

About Infinata
Infinata provides personalized technology solutions to help clients turn information into insight. Featuring exclusive biopharmaceutical intelligence and business development tools such as BioPharm Insight™ and BioPharm Clinical™, Infinata helps biopharma companies, CROs, service providers and financial markets firms understand and become active participants in their global industry. Infinata is a part of Mergermarket, a Financial Times Group company and a division of Pearson PLC. To learn more, visit

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Kristopher Sarajian
Email >
Visit website